

REMARKS

The Examiner has required restriction to one of three groups:

- I. Claims 1-2, drawn to a pharmaceutical composition comprising HMG CoA reductase inhibitor and pyridoxal 5'-phosphate.
- II. Claims 8-18, 24-25, 31-37, drawn to a method of treating patients at risk of cardiovascular diseases or diabetes or Alzheimer's disease.
- III. Claim 19, drawn to a method of treating hypercholesterolemia.

Without acquiescing to the statements made in the Restriction Requirement, Applicants hereby elect without traverse the claim of Group III (claim 19) for prosecution in the instant application. An election of species was not required for Group III claims.

Applicants have added new claims 38-49, which fall under restriction Group III (treating hypercholesterolemia). Support for the new claims can be found throughout the specification, including at page 5, lines 12-17; page 7, lines 19-24; page 8, lines 3-6; and page 10, line 22 to page 14, line 10.

Please cancel claims 1-2, 8-18, 24-25, and 31-37 without prejudice. Applicants reserve the right to claim the cancelled subject matter in one or more divisional applications.

SUMMARY

Applicants submit that the claims of the present application are in condition for allowance and notification to that effect is earnestly solicited. The Examiner is invited to contact Applicants' representative at the telephone number listed below, if the Examiner believes that doing so will advance prosecution.



Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332.5300

Date: September 15, 2009

/Brian R. Dorn/
Brian R. Dorn, Ph.D.
Reg. No. 57,395
BRD:smk